Not for release, publication or distribution in the United States, Canada, japan or Australia
Martinsried/München, 22 July 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announced today that the capital measure or the funding of its cancer immunotherapy programmes resolved on 27 June 2014 and completed on 15 July 2014 has been formally closed.
Following the entry of the share capital increase from EUR 10,889,950 by EUR 3,016,082 to EUR 13,906,032 in the commercial register on 17 July 2014, the 3,016,082 new shares were admitted to trading on the Regulated Market (Prime Standard) by the Frankfurt Stock Exchange on 18 July 2014. The new shares can be traded with seperate ISIN DE000A11QVD8, securities identification number WKN A11QVD and stock exchange symbol MDG9 from today up to 14 August 2014. From 15 August 2014 on, the new shares will have the same ISIN, securities identification number (WKN), and stock exchange symbol as the existing Medigene shares (ISIN: DE000A1X3W00, WKN: A1X3W0, MDG1).
The new convertible notes in the nominal amount of EUR 1.00 per note will be introduced to the Open Market (Quotation Board) of the Frankfurt Stock Exchange on 23 July 2014 (ISIN: DE000A12TWS6 / WKN: A12TWS, MDG5). Subject to certain non-conversion periods, the conversion right may be exercised by noteholders from 4 September 2014 until the maturity date at a conversion price of EUR 5.00 per share for conversion into up to 163,731 new shares. At the maturity date, which is two years after the issue date, the Company is entitled to require a mandatory conversion of the notes into shares.
Baader Bank AG acted as sole bookrunner and Trout Capital LLC acted as selling agent in the US.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partners. Medigene has various drug candidates in clinical development and it is developing highly innovative treatment platforms. For more information, please visit www.medigene.com.
Note: These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States, Germany or any other jurisdiction. The shares (the "Shares") of Medigene AG (the "Company") and the convertible bonds in relation to shares in Medigene AG (the "Convertible Bonds") may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of Shares or of the Convertible Bonds in the Company in the United States.
This publication constitutes neither an offer to sell nor a solicitation to buy securities. The new shares offered in connection with the rights offering have already been placed.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. These trademark may be owned or licensed in select locations only.
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please visit: www.medigene.de/unsubscribe